OMER

Omeros Corporation NASDAQ

Healthcare ·Biotechnology ·US · omeros.com

$14.91

Mkt Cap $1.1B

52w Low $2.95 81.4% of range 52w High $17.65

50d MA $11.90 200d MA $8.84

P/E (TTM) -285.8x

EV/EBITDA -10.8x

P/B —

Debt/Equity -2.0x

ROE 2.8%

P/FCF -9.4x

RSI (14) —

ATR (14) —

Beta 2.53

50d MA $11.90

200d MA $8.84

Avg Volume 1.1M

About

Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has comple…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 31, 2026	AMC	-0.55	3.14	+670.9%	10.56	+7.2%	+14.4%	+3.2%	+3.1%	+4.0%	+9.0%	—
Nov 13, 2025	AMC	-0.58	-0.19	+67.2%	6.28	+5.7%	+25.3%	+44.6%	+35.4%	+30.9%	+31.1%	—
Aug 14, 2025	AMC	-0.55	-0.53	+3.6%	4.12	+2.7%	+7.0%	+2.4%	+5.8%	+1.7%	+8.7%	—
May 15, 2025	AMC	-0.57	-0.65	-14.0%	3.95	-1.3%	-18.5%	-15.9%	-16.7%	-21.3%	-18.5%	—
Mar 31, 2025	AMC	-0.78	-0.63	+19.2%	8.22	+11.4%	-3.8%	-2.6%	-10.5%	-14.1%	-16.1%	—
Nov 13, 2024	AMC	-0.70	-0.64	+8.6%	4.19	+5.5%	+65.9%	+61.1%	+41.3%	+43.9%	+43.9%	—
Aug 7, 2024	AMC	-1.14	-1.12	+1.8%	4.15	-0.5%	-5.8%	-0.7%	+3.1%	-0.5%	-1.0%	—
May 15, 2024	AMC	-0.58	-0.74	-27.6%	4.17	-24.9%	-20.6%	-17.3%	-20.9%	-19.4%	-18.0%	—
Apr 1, 2024	AMC	-0.56	-0.63	-12.5%	3.19	-8.5%	-4.4%	-1.3%	-2.2%	+7.5%	+7.2%	—
Nov 9, 2023	AMC	-0.62	-0.82	-32.3%	1.26	-4.8%	-0.8%	+11.1%	+18.3%	+19.8%	+19.8%	—
Aug 9, 2023	AMC	-0.60	-0.70	-16.7%	4.33	-0.7%	-3.0%	-0.7%	-7.9%	-13.9%	-18.2%	—
May 9, 2023	AMC	-0.55	-0.63	-14.5%	5.00	+4.0%	+21.2%	+9.4%	+14.2%	+7.8%	+6.4%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 21	D. Boral Capital	Maintains	Buy → Buy	—	$13.47	$13.40	-0.5%	-1.6%	-0.7%	+0.4%	+0.4%	+9.4%
Jan 27	D. Boral Capital	Maintains	Buy → Buy	—	$11.53	$11.53	+0.0%	+9.9%	+2.4%	+3.6%	+1.4%	+1.6%
Jan 8	HC Wainwright & Co.	Maintains	Buy → Buy	—	$14.09	$14.52	+3.1%	-4.5%	-11.4%	-9.0%	-10.4%	-7.2%
Jan 8	D. Boral Capital	Maintains	Buy → Buy	—	$14.09	$14.52	+3.1%	-4.5%	-11.4%	-9.0%	-10.4%	-7.2%
Dec 24	D. Boral Capital	Maintains	Buy → Buy	—	$8.75	$16.44	+87.9%	+75.5%	+79.5%	+89.4%	+93.8%	+96.3%
Dec 1	D. Boral Capital	Maintains	Buy → Buy	—	$9.69	$9.83	+1.4%	-0.1%	-2.7%	+9.6%	+13.8%	+12.0%
Nov 14	D. Boral Capital	Maintains	Buy → Buy	—	$6.28	$6.64	+5.7%	+25.3%	+44.6%	+35.4%	+30.9%	+31.1%
Oct 16	D. Boral Capital	Maintains	Buy → Buy	—	$10.42	$9.15	-12.2%	-5.7%	-22.2%	-20.8%	-24.5%	-25.7%
Oct 15	HC Wainwright & Co.	Maintains	Buy → Buy	—	$4.10	$11.59	+182.7%	+154.1%	+139.8%	+97.8%	+101.2%	+92.0%
Oct 15	WBB Securities	Maintains	Strong Buy → Strong Buy	—	$4.10	$11.59	+182.7%	+154.1%	+139.8%	+97.8%	+101.2%	+92.0%
Oct 15	Needham	Maintains	Hold → Hold	—	$4.10	$11.59	+182.7%	+154.1%	+139.8%	+97.8%	+101.2%	+92.0%
Oct 15	D. Boral Capital	Maintains	Buy → Buy	—	$4.10	$11.59	+182.7%	+154.1%	+139.8%	+97.8%	+101.2%	+92.0%
Sep 3	D. Boral Capital	Maintains	Buy → Buy	—	$4.29	$4.24	-1.2%	-2.6%	-2.6%	-2.8%	-1.9%	-0.7%
Aug 15	D. Boral Capital	Maintains	Buy → Buy	—	$4.12	$4.23	+2.7%	+7.0%	+2.4%	+5.8%	+1.7%	+8.7%
Aug 15	Needham	Maintains	Hold → Hold	—	$4.12	$4.23	+2.7%	+7.0%	+2.4%	+5.8%	+1.7%	+8.7%
Jul 25	D. Boral Capital	Maintains	Buy → Buy	—	$3.59	$3.86	+7.5%	+6.7%	+15.6%	+10.6%	+7.2%	+7.8%
Jun 30	D. Boral Capital	Maintains	Buy → Buy	—	$3.20	$3.20	+0.0%	-6.2%	-7.2%	-3.4%	+0.0%	-3.8%
May 16	Needham	Maintains	Hold → Hold	—	$3.95	$3.90	-1.3%	-18.5%	-15.9%	-16.7%	-21.3%	-18.5%
May 13	D. Boral Capital	Maintains	Buy → Buy	—	$3.80	$4.22	+11.1%	+16.6%	+3.4%	+3.9%	-15.3%	-12.6%
May 7	D. Boral Capital	Maintains	Buy → Buy	—	$6.34	$6.33	-0.2%	+0.2%	-0.5%	-2.5%	-40.1%	-30.1%
Apr 11	D. Boral Capital	Maintains	Buy → Buy	—	$5.86	$5.87	+0.2%	+14.8%	+19.3%	+17.2%	+15.4%	+15.7%
Apr 1	D. Boral Capital	Maintains	Buy → Buy	—	$8.22	$9.16	+11.4%	-3.8%	-2.6%	-10.5%	-14.1%	-16.1%
Apr 1	Needham	Maintains	Hold → Hold	—	$8.22	$9.16	+11.4%	-3.8%	-2.6%	-10.5%	-14.1%	-16.1%
Mar 21	D. Boral Capital	Maintains	Buy → Buy	—	$9.10	$8.97	-1.4%	+0.0%	-0.9%	+0.7%	-6.4%	-2.0%
Feb 20	D. Boral Capital	Maintains	Buy → Buy	—	$9.25	$9.54	+3.1%	+3.9%	-0.8%	-6.2%	-8.6%	-5.4%
Jan 17	Needham	Maintains	Hold → Hold	—	$9.18	$9.18	+0.0%	+1.6%	-0.3%	+1.2%	-1.9%	-8.8%
Jan 16	D. Boral Capital	Maintains	Buy → Buy	—	$8.90	$9.11	+2.4%	+3.1%	+4.8%	+2.8%	+4.4%	+1.2%
Dec 19	Needham	Maintains	Hold → Hold	—	$7.46	$9.71	+30.2%	+37.3%	+38.2%	+35.5%	+34.0%	+40.2%
Nov 10	Cantor Fitzgerald	Downgrade	Overweight → Neutral	—	$1.26	$1.20	-4.8%	-0.8%	+11.1%	+18.3%	+19.8%	+19.8%
Dec 8	UBS	Downgrade	Buy → Neutral	—	$2.22	$2.10	-5.4%	-0.9%	-7.2%	-4.1%	+1.4%	-10.8%
Nov 8	BofA Securities	Downgrade	Neutral → Underperform	—	$3.28	$3.34	+1.8%	-2.4%	-14.0%	-18.9%	-16.5%	-13.1%
Jun 8	BofA Securities	Downgrade	Buy → Neutral	—	$2.42	$2.30	-5.0%	-9.9%	-11.6%	-13.6%	-16.5%	-19.4%
Oct 19	HC Wainwright & Co.	Maintains	Buy → Buy	—	$5.67	$5.82	+2.6%	+9.7%	+12.9%	+13.9%	+14.5%	+11.5%
Oct 8	JP Morgan	Downgrade	Neutral → Underweight	—	$7.43	$7.09	-4.6%	-9.8%	-3.6%	-4.2%	-0.7%	+4.0%
Oct 6	HC Wainwright & Co.	Maintains	Buy → Buy	—	$7.08	$6.99	-1.3%	+1.8%	+4.9%	-5.4%	+1.1%	+0.6%
Oct 4	Maxim Group	Downgrade	Buy → Hold	—	$8.54	$8.08	-5.4%	-14.8%	-17.1%	-15.6%	-13.0%	-21.5%
Jun 18	WBB Securities	Maintains	Strong Buy → Strong Buy	—	$14.97	$15.19	+1.5%	+0.6%	+2.3%	+3.3%	+3.2%	+3.8%
Apr 26	HC Wainwright & Co.	Maintains	Buy → Buy	—	$18.65	$18.65	+0.0%	-2.7%	-3.2%	-3.5%	-4.0%	-5.3%
Feb 1	UBS	Maintains	Buy → Buy	—	$19.46	$19.88	+2.2%	+5.1%	+8.2%	+11.4%	+11.3%	+8.6%
Jan 20	HC Wainwright & Co.	Maintains	Buy → Buy	—	$19.46	$19.87	+2.1%	-2.4%	-4.3%	+1.1%	+0.2%	-1.2%
Jan 4	HC Wainwright & Co.	Maintains	Buy → Buy	—	$14.29	$14.30	+0.1%	+1.6%	+1.6%	+5.3%	+10.6%	+12.0%
Oct 20	BofA Securities	Maintains	Buy → Buy	—	$11.08	$11.71	+5.7%	+1.6%	+0.6%	-0.3%	-3.8%	-7.8%
Sep 1	Wedbush	Maintains	Neutral → Neutral	—	$11.95	$11.86	-0.8%	-9.3%	-11.6%	-13.6%	-16.3%	-11.3%
Aug 21	HC Wainwright & Co.	Maintains	Buy → Buy	—	$12.95	$12.85	-0.8%	-3.9%	-6.9%	-9.0%	-7.3%	-9.6%
Dec 2	H.C. Wainwright	Maintains	Buy → Buy	—	$14.80	$14.59	-1.4%	-2.4%	-2.9%	+3.0%	-10.1%	-11.1%
May 6	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$19.62	$19.46	-0.8%	-0.1%	-8.9%	-6.3%	-5.4%	-1.5%
Aug 10	Maxim Group	Maintains	Buy → Buy	—	$21.70	$22.28	+2.7%	-18.3%	-11.6%	-5.0%	-7.2%	-5.4%
May 17	Wedbush	Maintains	Neutral → Neutral	—	$20.01	$19.90	-0.5%	+1.2%	+0.5%	+3.9%	+3.9%	-1.1%
Mar 23	Maxim Group	Maintains	Buy → Buy	—	$15.75	$14.75	-6.3%	-10.5%	-22.0%	-22.3%	-24.4%	-29.1%
Mar 23	Wedbush	Downgrade	Outperform → Neutral	—	$15.75	$14.75	-6.3%	-10.5%	-22.0%	-22.3%	-24.4%	-29.1%

Recent Filings

8-K · 8.01 !! High

Kyverna Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement

Eli Lilly acquired Kyverna Therapeutics for an undisclosed amount, expanding its immunology portfolio with Kyverna's cell therapy candidates.

May 4

8-K · 5.02 !!! Very High

Sagimet Biosciences Inc. Series A -- 8-K 5.02: Executive Change

Sagimet Biosciences' Chief Medical Officer Eduardo Martins resigned, potentially impacting clinical development leadership and investor confidence in the biotech company's pipeline progression.

Apr 21

8-K

Unknown — 8-K Filing

Omeros reported full-year 2025 financial results, signaling operational updates investors should monitor for revenue trends, profitability, and pipeline progress affecting future growth prospects.

Mar 31

Data updated apr 26, 2026 5:22pm · Source: massive.com